220 related articles for article (PubMed ID: 35938381)
21. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
[TBL] [Abstract][Full Text] [Related]
23. Trajectories of CD4
Taramasso L; Falletta A; Ricci E; Orofino G; Squillace N; Menzaghi B; De Socio GV; Molteni C; Pellicanò GF; Gulminetti R; Madeddu G; Sarchi E; Vichi F; Celesia BM; Bonfanti P; Di Biagio A;
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366413
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study.
Pujari S; Gaikwad S; Panchawagh S; Chitalikar A; Joshi K; Rohekar C; Dabhade D; Bele V
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):204-215. PubMed ID: 38063004
[TBL] [Abstract][Full Text] [Related]
25. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
27. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
[TBL] [Abstract][Full Text] [Related]
28. Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Bendala-Estrada AD; Diaz-Almiron M; Busca C; Mican R; Cadiñanos J; Montes ML; Martin-Carbonero L; Valencia E; Montejano R; Delgado-Hierro A; Bernardino JI
HIV Med; 2023 May; 24(5):558-567. PubMed ID: 36394195
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
Wei Y; Li J; Xu R; Wen L; Deng Y; He L; Zhong H; Wang Y
Chin Med J (Engl); 2023 Nov; 136(22):2677-2685. PubMed ID: 37914678
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM; Brites C; Cheng CY; Osiyemi O; Galera C; Hocqueloux L; Maggiolo F; Degen O; Taylor S; Blair E; Man C; Wynne B; Oyee J; Underwood M; Curtis L; Bontempo G; van Wyk J
Clin Infect Dis; 2023 Feb; 76(4):720-729. PubMed ID: 35235656
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan.
Anderson SJ; Hsu CY; Ou HT; Ko NY; Yang CT; Lopes S
Value Health Reg Issues; 2021 May; 24():216-223. PubMed ID: 33857719
[TBL] [Abstract][Full Text] [Related]
32. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
Radford M; Parks DC; Ferrante S; Punekar Y
AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906
[TBL] [Abstract][Full Text] [Related]
34. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C;
Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976
[TBL] [Abstract][Full Text] [Related]
35. Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses.
Benson P; Kuretski J; Donovan C; Harper G; Merrill D; Metzner AA; Mycock K; Wallis H; Brogan AP; Patarroyo J; Oglesby A
Infect Dis Ther; 2024 Apr; 13(4):875-889. PubMed ID: 38570444
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.
Palacios R; Gómez-Ayerbe C; Casado JL; Tejerina F; Montes ML; Castaño M; Ocampo A; Rial D; Ribera E; Galindo MJ; Hidalgo C; Fariñas C; Montero M; Payeras T; Fanjul F; de la Torre J; Santos J
HIV Med; 2023 Aug; 24(8):933-937. PubMed ID: 37016556
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I; Alejos B; Hernando V; Viñuela L; Vera García M; Rial-Crestelo D; Pérez Elías MJ; Albendín Iglesias H; Peraire J; Tiraboschi J; Díaz A; Moreno S; Jarrín I;
J Antimicrob Chemother; 2023 Jun; 78(6):1423-1432. PubMed ID: 37099559
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
39. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
40. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
